A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

This study is testing a new drug combination — WSD0922-FU plus osimertinib — for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that carries an EGFR mutation. Osimertinib is a standard EGFR-targeted therapy, and the study investigates whether WSD0922-FU can enhance or overcome resistance to it. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic NSCLC - Your cancer has been tested and found to carry an EGFR-sensitizing mutation - You have at least one measurable tumor on imaging - Your overall health is rated good (ECOG 0 or 1) - Your organs are functioning adequately - You are willing to use effective contraception if applicable - You have provided a blood or tissue sample for genetic testing **You may NOT be eligible if...** - You have received chemotherapy, radiation, or targeted therapy within 4 weeks before starting the study - You have previously received more than two EGFR-targeted therapies (for Part A of the study) - You have had recent major surgery or plan to have surgery during the trial - You are taking strong CYP3A4 inhibitors or inducers - Your prior treatment side effects have not recovered adequately Talk to your doctor to see if this trial is right for you.